Consultation documents published: Consultation on the in vitro data on neutralising monoclonal antibodies for COVID-19: methods framework

In light of the conclusions of the panel in the appeal against the recommendations in the technology appraisal of molnupiravir, remdesivir and tixagevimab plus cilgavimab for treating COVID-19, NICE is holding a 4-week consultation on the in vitro data on neutralising monoclonal antibodies for COVID-19: methods framework which is available on the NICE website.

In addition, this document was initially developed in December 2022/January 2023. Since then, there have been changes in the amount and type of data that is collected and published, with a substantial reduction in the number of in vitro data studies. Therefore, key questions that we are seeking feedback on are: is the in vitro data methods framework still useful for decision-making, and if not, what other alternative approaches could NICE consider to meet the challenge of treatment effectiveness changing with variants?

Providing comments

Please submit your comments using the consultation questions and comments form available on the NICE website. Please use Microsoft Word for your responses.

In order for your views to be included in the consultation process, your comments must be submitted before 5pm on Wednesday 29 November 2023 via TATeam4@nice.org.uk.

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.